Holen Sie sich die Stockscreener-App
31.49
5.07%
1.52
Handel nachbörslich:
31.55
0.06
+0.19%
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Price to book forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Enterprise value to revenue forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to earnings forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Enterprise value to EBITDA forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to sales forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics Hldgs Price Target Maintained With a $40.00/Share by HC Wainwright & Co. - Moomoo
Hemab Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:COAG) - TradingView
COAG Forecast — Price Target — Prediction for 2027 - TradingView
COAG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress - The Manila Times
Hemab brings nine bleeding-disorder studies to ISTH 2026 in Paris - Stock Titan
Enterprise value to EBIT forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Holdings, Inc.(NasdaqGS: COAG) added to S&P TMI Index - marketscreener.com
This GE Vernova analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
COAG Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Hemab Therapeutics (COAG) stake rises as RA Capital buys 67,669 shares - Stock Titan
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):